Ajax Health, the company formed last year by a pair of private equity giants to manage their medical device investments, said today that it raised a Series B round of $120 million.
In May 2017 KKR and Aisling Capital joined to launch Ajax, tapping Spirox chairman & CEO Duke Rohlen to lead it. Rohlen is the former president of FoxHollow Technologies and the founder & former chief executive of CV Ingenuity.
Yesterday Ajax said the Series B round included new backers Iconiq Capital, HealthQuest Capital, Polaris Partners, WTI and “select other individual and large family office investors.” KKR and Aisling Capital also participated, the company said.
“We are thrilled to welcome into Ajax this exceptional new investor syndicate. Their confidence in Ajax underscores the opportunity that Ajax sees to accelerate investment and innovation in an undervalued medical technology sector. There is a significant need in the medical device space for capital to be deployed into differentiated technologies that leverage seasoned operational teams and rational business models. The new group of investors in Ajax recognizes this opportunity and, with this investment, catalyzes the opportunity for important therapeutic innovation,” Rohlen said in prepared remarks.
Ajax last year led a $45 million round for Advanced Cardiac Therapies, where Rohlen is also CEO. ACT is developing a next-generation ablation catheter.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.